OBJECTIVE: The objective of this study was to describe cases of sarcoid arthritis in firefighters from the Fire Department of the City of New York (FDNY) who worked at the World Trade Center (WTC) site. METHODS: All WTC-exposed FDNY firefighters with sarcoidosis and related chronic inflammatory arthritis (n = 11) are followed jointly by the FDNY-WTC Health Program and the Rheumatology Division at the Hospital for Special Surgery. Diagnoses of sarcoidosis were based on clinical, radiographic, and pathological criteria. Patient characteristics, WTC exposure information, smoking status, date of diagnosis, and pulmonary findings were obtained from FDNY-WTC database. Joint manifestations (symptoms and duration, distribution of joints involved), radiographic findings, and treatment responses were obtained from chart review. RESULTS: Nine of 60 FDNY firefighters who developed sarcoidosis since 9/11/2001 presented with polyarticular arthritis. Two others diagnosed pre-9/11/2001 developed sarcoid arthritis after WTC exposure. All 11 were never cigarette smokers, and all performed rescue/recovery at the WTC site within 3 days of the attacks. All had biopsy-proven pulmonary sarcoidosis, and all required additional disease-modifying antirheumatic drugs for adequate control (stepwise progression from hydroxychloroquine to methotrexate to anti-tumor necrosis factor α agents) of their joint manifestations. CONCLUSIONS: Chronic inflammatory polyarthritis appears to be an important manifestation of sarcoidosis in FDNY firefighters with sarcoidosis and WTC exposure. Their arthritis is chronic and, unlike arthritis in non-WTC-exposed sarcoid patients, inadequately responsive to conventional oral disease-modifying antirheumatic drugs, often requiring anti-tumor necrosis factor α agents. Further studies are needed to determine the generalizability of these findings to other groups with varying levels of WTC exposure or with other occupational/environmental exposures.
OBJECTIVE: The objective of this study was to describe cases of sarcoid arthritis in firefighters from the Fire Department of the City of New York (FDNY) who worked at the World Trade Center (WTC) site. METHODS: All WTC-exposed FDNY firefighters with sarcoidosis and related chronic inflammatory arthritis (n = 11) are followed jointly by the FDNY-WTC Health Program and the Rheumatology Division at the Hospital for Special Surgery. Diagnoses of sarcoidosis were based on clinical, radiographic, and pathological criteria. Patient characteristics, WTC exposure information, smoking status, date of diagnosis, and pulmonary findings were obtained from FDNY-WTC database. Joint manifestations (symptoms and duration, distribution of joints involved), radiographic findings, and treatment responses were obtained from chart review. RESULTS: Nine of 60 FDNY firefighters who developed sarcoidosis since 9/11/2001 presented with polyarticular arthritis. Two others diagnosed pre-9/11/2001 developed sarcoid arthritis after WTC exposure. All 11 were never cigarette smokers, and all performed rescue/recovery at the WTC site within 3 days of the attacks. All had biopsy-proven pulmonary sarcoidosis, and all required additional disease-modifying antirheumatic drugs for adequate control (stepwise progression from hydroxychloroquine to methotrexate to anti-tumor necrosis factor α agents) of their joint manifestations. CONCLUSIONS: Chronic inflammatory polyarthritis appears to be an important manifestation of sarcoidosis in FDNY firefighters with sarcoidosis and WTC exposure. Their arthritis is chronic and, unlike arthritis in non-WTC-exposed sarcoid patients, inadequately responsive to conventional oral disease-modifying antirheumatic drugs, often requiring anti-tumor necrosis factor α agents. Further studies are needed to determine the generalizability of these findings to other groups with varying levels of WTC exposure or with other occupational/environmental exposures.
Authors: David J Prezant; Michael Weiden; Gisela I Banauch; Georgeann McGuinness; William N Rom; Thomas K Aldrich; Kerry J Kelly Journal: N Engl J Med Date: 2002-09-09 Impact factor: 91.245
Authors: Michael D Weiden; Bushra Naveed; Sophia Kwon; Leopoldo N Segal; Soo Jung Cho; Jun Tsukiji; Rohan Kulkarni; Ashley L Comfort; Kusali J Kasturiarachchi; Colette Prophete; Mitchell D Cohen; Lung-Chi Chen; William N Rom; David J Prezant; Anna Nolan Journal: PLoS One Date: 2012-07-18 Impact factor: 3.240
Authors: Paul J Lioy; Clifford P Weisel; James R Millette; Steven Eisenreich; Daniel Vallero; John Offenberg; Brian Buckley; Barbara Turpin; Mianhua Zhong; Mitchell D Cohen; Colette Prophete; Ill Yang; Robert Stiles; Glen Chee; Willie Johnson; Robert Porcja; Shahnaz Alimokhtari; Robert C Hale; Charles Weschler; Lung Chi Chen Journal: Environ Health Perspect Date: 2002-07 Impact factor: 9.031
Authors: Kerry M Hena; Jennifer Yip; Nadia Jaber; David Goldfarb; Kelly Fullam; Krystal Cleven; William Moir; Rachel Zeig-Owens; Mayris P Webber; Daniel M Spevack; Marc A Judson; Lisa Maier; Andrew Krumerman; Anthony Aizer; Simon D Spivack; Jessica Berman; Thomas K Aldrich; David J Prezant Journal: Chest Date: 2017-10-21 Impact factor: 9.410
Authors: M P Webber; W Moir; R Zeig-Owens; M S Glaser; N Jaber; C Hall; J Berman; B Qayyum; K Loupasakis; K Kelly; D J Prezant Journal: Arthritis Rheumatol Date: 2015-05 Impact factor: 10.995
Authors: Lisa M Gargano; Kimberly Mantilla; Monique Fairclough; Shengchao Yu; Robert M Brackbill Journal: Int J Environ Res Public Health Date: 2018-02-03 Impact factor: 3.390